Anti-CD20 monoclonal antibodies: historical and future perspectives.
Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal, malignant and auto-immune B-lymphocytes by rituximab has demonstrated substantial benefits for patients with a variety of B-cell lymphomas, as well as some with autoimmune disorders. There has been a notable increase in the survival rates from B-cell lymphoma in the decade since anti-CD20 therapy was introduced.
Tenovus Laboratory, Cancer Sciences Division, Southampton University School of Medicine, General Hospital, Southampton SO16 6YD, UK.
Sean H
SH
Lim
Stephen A
SA
Beers
Ruth R
RR
French
Peter W M
PW
Johnson
Martin J
MJ
Glennie
Mark S
MS
Cragg
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018951:Antigens, CD20 / Q000235:genetics / Q000276:immunology*; D005544:Forecasting; D006801:Humans; D016393:Lymphoma, B-Cell / Q000276:immunology* / Q000473:pathology / Q000628:therapy*
D000911:Antibodies, Monoclonal; D018951:Antigens, CD20